Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1801 to 1811 of 1811 entries
Sorted by: Best Match Show Resources per page
Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways.

Frontiers in neurology

Engelhard HH, Willis AJ, Hussain SI, Papavasiliou G, Banner DJ, Kwasnicki A, Lakka SS, Hwang S, Shokuhfar T, Morris SC, Liu B.
PMID: 33329349
Front Neurol. 2020 Nov 27;11:596632. doi: 10.3389/fneur.2020.596632. eCollection 2020.

Magnetic nanoparticles (MNPs) have potential for enhancing drug delivery in selected cancer patients, including those which have cells that have disseminated within cerebrospinal fluid (CSF) pathways. Here, we present data related to the creation and

Cite
Engelhard HH, Willis AJ, Hussain SI, et al. Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways. Front Neurol. 2020;11:596632doi: 10.3389/fneur.2020.596632.
Engelhard, H. H., Willis, A. J., Hussain, S. I., Papavasiliou, G., Banner, D. J., Kwasnicki, A., Lakka, S. S., Hwang, S., Shokuhfar, T., Morris, S. C., & Liu, B. (2020). Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways. Frontiers in neurology, 11596632. https://doi.org/10.3389/fneur.2020.596632
Engelhard, Herbert H, et al. "Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways." Frontiers in neurology vol. 11 (2020): 596632. doi: https://doi.org/10.3389/fneur.2020.596632
Engelhard HH, Willis AJ, Hussain SI, Papavasiliou G, Banner DJ, Kwasnicki A, Lakka SS, Hwang S, Shokuhfar T, Morris SC, Liu B. Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways. Front Neurol. 2020 Nov 27;11:596632. doi: 10.3389/fneur.2020.596632. eCollection 2020. PMID: 33329349; PMCID: PMC7729165.
Copy Download .nbib Format: NLM
2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'- Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity.

Medicinal chemistry (Shariqah (United Arab Emirates))

Lu Y, Zhu L, Cai R, Li Y, Zhao Y.
PMID: 33222676
Med Chem. 2020 Nov 19; doi: 10.2174/1573406416666201120102250. Epub 2020 Nov 19.

BACKGROUND: Podophyllotoxin is a natural lignan which possesses anticancer and antiviral activities. Etoposide and teniposide are semisynthetic glycoside derivatives of podophyllotoxin and are increasingly used in cancer medicine.OBJECTIVE: The present work was aimed to design and synthesize a series...

Cite
Lu Y, Zhu L, Cai R, et al. 2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'- Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity. Med Chem. 2020;doi: 10.2174/1573406416666201120102250.
Lu, Y., Zhu, L., Cai, R., Li, Y., & Zhao, Y. (2020). 2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'- Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity. Medicinal chemistry (Shariqah (United Arab Emirates)), . https://doi.org/10.2174/1573406416666201120102250
Lu, Yapeng, et al. "2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'- Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity." Medicinal chemistry (Shariqah (United Arab Emirates)) vol. (2020). doi: https://doi.org/10.2174/1573406416666201120102250
Lu Y, Zhu L, Cai R, Li Y, Zhao Y. 2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'- Demethylepipodophyllotoxin: De novo Synthesis and Anticancer Activity. Med Chem. 2020 Nov 19; doi: 10.2174/1573406416666201120102250. Epub 2020 Nov 19. PMID: 33222676.
Copy Download .nbib Format: NLM
Medical Approaches in Adrenocortical Carcinoma.

Biomedicines

Paragliola RM, Corsello A, Locantore P, Papi G, Pontecorvi A, Corsello SM.
PMID: 33260476
Biomedicines. 2020 Nov 29;8(12). doi: 10.3390/biomedicines8120551.

Adrenocortical carcinoma (ACC) represents one of the most aggressive endocrine tumors. In spite of a correct therapeutic strategy based on a multidisciplinary approach between endocrinologist, surgeon and oncologist, the prognosis is often poor. Surgery is the mainstay treatment in...

Cite
Paragliola RM, Corsello A, Locantore P, et al. Medical Approaches in Adrenocortical Carcinoma. Biomedicines. 2020;8(12)doi: 10.3390/biomedicines8120551.
Paragliola, R. M., Corsello, A., Locantore, P., Papi, G., Pontecorvi, A., & Corsello, S. M. (2020). Medical Approaches in Adrenocortical Carcinoma. Biomedicines, 8(12), . https://doi.org/10.3390/biomedicines8120551
Paragliola, Rosa Maria, et al. "Medical Approaches in Adrenocortical Carcinoma." Biomedicines vol. 8,12 (2020). doi: https://doi.org/10.3390/biomedicines8120551
Paragliola RM, Corsello A, Locantore P, Papi G, Pontecorvi A, Corsello SM. Medical Approaches in Adrenocortical Carcinoma. Biomedicines. 2020 Nov 29;8(12). doi: 10.3390/biomedicines8120551. PMID: 33260476; PMCID: PMC7760807.
Copy Download .nbib Format: NLM
Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids.

Frontiers in medicine

Aoyagi T, Sato Y, Baba H, Shiga T, Seike I, Niitsuma Sugaya I, Takei K, Iwasaki Y, Oshima K, Kanamori H, Yoshida M, Saito K, Tokuda K, Kaku M.
PMID: 34631741
Front Med (Lausanne). 2021 Sep 23;8:718641. doi: 10.3389/fmed.2021.718641. eCollection 2021.

Acute respiratory distress syndrome (ARDS) is the leading cause of mortality in hospitalized patients with coronavirus disease 2019 (COVID-19) because of limited effective therapies. During infection, the accumulation and activation of macrophages and monocytes in the lungs induce inflammatory...

Cite
Aoyagi T, Sato Y, Baba H, et al. Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. Front Med (Lausanne). 2021;8:718641doi: 10.3389/fmed.2021.718641.
Aoyagi, T., Sato, Y., Baba, H., Shiga, T., Seike, I., Niitsuma Sugaya, I., Takei, K., Iwasaki, Y., Oshima, K., Kanamori, H., Yoshida, M., Saito, K., Tokuda, K., & Kaku, M. (2021). Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. Frontiers in medicine, 8718641. https://doi.org/10.3389/fmed.2021.718641
Aoyagi, Tetsuji, et al. "Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids." Frontiers in medicine vol. 8 (2021): 718641. doi: https://doi.org/10.3389/fmed.2021.718641
Aoyagi T, Sato Y, Baba H, Shiga T, Seike I, Niitsuma Sugaya I, Takei K, Iwasaki Y, Oshima K, Kanamori H, Yoshida M, Saito K, Tokuda K, Kaku M. Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. Front Med (Lausanne). 2021 Sep 23;8:718641. doi: 10.3389/fmed.2021.718641. eCollection 2021. PMID: 34631741; PMCID: PMC8496678.
Copy Download .nbib Format: NLM
An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces.

Pharmaceuticals (Basel, Switzerland)

Portilha-Cunha MF, Ramos S, Silva AMT, Norton P, Alves A, Santos MSF.
PMID: 34451851
Pharmaceuticals (Basel). 2021 Jul 31;14(8). doi: 10.3390/ph14080754.

Cytostatics are drugs used in cancer treatment, which pose serious risks to healthcare workers. Dermal absorption via surface contamination is the key exposure route; thus, rapid, reliable, and validated analytical methods for multicomponent detection are crucial to identify the...

Cite
Portilha-Cunha MF, Ramos S, Silva AMT, et al. An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces. Pharmaceuticals (Basel). 2021;14(8)doi: 10.3390/ph14080754.
Portilha-Cunha, M. F., Ramos, S., Silva, A. M. T., Norton, P., Alves, A., & Santos, M. S. F. (2021). An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces. Pharmaceuticals (Basel, Switzerland), 14(8), . https://doi.org/10.3390/ph14080754
Portilha-Cunha, Maria Francisca, et al. "An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces." Pharmaceuticals (Basel, Switzerland) vol. 14,8 (2021). doi: https://doi.org/10.3390/ph14080754
Portilha-Cunha MF, Ramos S, Silva AMT, Norton P, Alves A, Santos MSF. An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces. Pharmaceuticals (Basel). 2021 Jul 31;14(8). doi: 10.3390/ph14080754. PMID: 34451851; PMCID: PMC8398795.
Copy Download .nbib Format: NLM
Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review.

Journal of pediatric hematology/oncology

Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G.
PMID: 33323880
J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033.

Pancreatoblastoma (PB) is a tumor typically seen in childhood. Despite its rarity, there are some internationally agreed recommendations for its first-line treatment, but very little is known about the management of relapse. We reviewed the literature on the treatment...

Cite
Reggiani G, Affinita MC, Dall'Igna P, et al. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021;43(8):288-293doi: 10.1097/MPH.0000000000002033.
Reggiani, G., Affinita, M. C., Dall'Igna, P., Virgone, C., Sorbara, S., & Bisogno, G. (2021). Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. Journal of pediatric hematology/oncology, 43(8), 288-293. https://doi.org/10.1097/MPH.0000000000002033
Reggiani, Giulia, et al. "Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review." Journal of pediatric hematology/oncology vol. 43,8 (2021): 288-293. doi: https://doi.org/10.1097/MPH.0000000000002033
Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033. PMID: 33323880.
Copy Download .nbib Format: NLM
Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma.

Pediatric blood & cancer

Grümme L, Biewald E, Reschke M, Fischhuber K, Hanbücken A, Schlüter S, Müller B, Kiefer T, Göricke S, Geismar D, Ryl T, Sirin S, Wieland R, Timmermann B, Lohmann D, Ebinger M, Brecht IB, Schönberger S, Schwab C, Eggert A, Süsskind D, Ritter-Sovinz P, Bechrakis NE, Ketteler P.
PMID: 34606174
Pediatr Blood Cancer. 2021 Oct 04;e29362. doi: 10.1002/pbc.29362. Epub 2021 Oct 04.

BACKGROUND: Eye-preserving therapy in retinoblastoma comprises systemic chemotherapy, but studies analyzing the efficacy of different chemotherapy regimens are scarce.METHODS: The efficacy and side effects of two different eye-preserving chemotherapy regimens containing either vincristine, etoposide, and carboplatin (VEC) or cyclophosphamide,...

Cite
Grümme L, Biewald E, Reschke M, et al. Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Pediatr Blood Cancer. 2021;e29362doi: 10.1002/pbc.29362.
Grümme, L., Biewald, E., Reschke, M., Fischhuber, K., Hanbücken, A., Schlüter, S., Müller, B., Kiefer, T., Göricke, S., Geismar, D., Ryl, T., Sirin, S., Wieland, R., Timmermann, B., Lohmann, D., Ebinger, M., Brecht, I. B., Schönberger, S., Schwab, C., Eggert, A., Süsskind, D., Ritter-Sovinz, P., Bechrakis, N. E., & Ketteler, P. (2021). Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Pediatric blood & cancer, e29362. https://doi.org/10.1002/pbc.29362
Grümme, Lea, et al. "Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma." Pediatric blood & cancer vol. (2021): e29362. doi: https://doi.org/10.1002/pbc.29362
Grümme L, Biewald E, Reschke M, Fischhuber K, Hanbücken A, Schlüter S, Müller B, Kiefer T, Göricke S, Geismar D, Ryl T, Sirin S, Wieland R, Timmermann B, Lohmann D, Ebinger M, Brecht IB, Schönberger S, Schwab C, Eggert A, Süsskind D, Ritter-Sovinz P, Bechrakis NE, Ketteler P. Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Pediatr Blood Cancer. 2021 Oct 04;e29362. doi: 10.1002/pbc.29362. Epub 2021 Oct 04. PMID: 34606174.
Copy Download .nbib Format: NLM
Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.

Molecular biology reports

Ma Y, North BJ, Shu J.
PMID: 34476738
Mol Biol Rep. 2021 Sep;48(9):6589-6601. doi: 10.1007/s11033-021-06665-7. Epub 2021 Sep 02.

DNA topoisomerases II (TOP2) are peculiar enzymes (TOP2α and TOP2β) that modulate the conformation of DNA by momentarily breaking double-stranded DNA to allow another strand to pass through, and then rejoins the DNA phosphodiester backbone. TOP2α and TOP2β play...

Cite
Ma Y, North BJ, Shu J. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy. Mol Biol Rep. 2021;48(9):6589-6601doi: 10.1007/s11033-021-06665-7.
Ma, Y., North, B. J., & Shu, J. (2021). Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy. Molecular biology reports, 48(9), 6589-6601. https://doi.org/10.1007/s11033-021-06665-7
Ma, Ying, et al. "Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy." Molecular biology reports vol. 48,9 (2021): 6589-6601. doi: https://doi.org/10.1007/s11033-021-06665-7
Ma Y, North BJ, Shu J. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy. Mol Biol Rep. 2021 Sep;48(9):6589-6601. doi: 10.1007/s11033-021-06665-7. Epub 2021 Sep 02. PMID: 34476738; PMCID: PMC8589089.
Copy Download .nbib Format: NLM
Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study.

Cancer management and research

Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S.
PMID: 34916851
Cancer Manag Res. 2021 Dec 10;13:9085-9093. doi: 10.2147/CMAR.S343572. eCollection 2021.

BACKGROUND: Primary hepatic neuroendocrine carcinoma (PHNEC) is a rare liver tumor, and there is no clear therapeutic recommendation for patients with advanced PHNEC. This study aims to compare the efficacy of platinum-based chemotherapy (etoposide combined with cisplatin/carboplatin, EP/EC) and...

Cite
Li S, Niu M, Deng W, et al. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res. 2021;13:9085-9093doi: 10.2147/CMAR.S343572.
Li, S., Niu, M., Deng, W., Li, N., Wei, C., Zhang, C., & Luo, S. (2021). Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer management and research, 139085-9093. https://doi.org/10.2147/CMAR.S343572
Li, Shuyi, et al. "Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study." Cancer management and research vol. 13 (2021): 9085-9093. doi: https://doi.org/10.2147/CMAR.S343572
Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res. 2021 Dec 10;13:9085-9093. doi: 10.2147/CMAR.S343572. eCollection 2021. PMID: 34916851; PMCID: PMC8671721.
Copy Download .nbib Format: NLM
Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.

Neuroendocrinology

Abdel-Rahman O, Koski SL.
PMID: 34649258
Neuroendocrinology. 2021 Oct 14; doi: 10.1159/000520193. Epub 2021 Oct 14.

OBJECTIVE: This study aimed to assess the survival differences between cisplatin/etoposide versus carboplatin/etoposide chemotherapy regimens in the management of patients with extrapulmonary neuroendocrine carcinomas (NECs).METHODS: Administrative cancer care databases in the province of Alberta, Canada, were reviewed, and patients...

Cite
Abdel-Rahman O, Koski SL. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study. Neuroendocrinology. 2021;doi: 10.1159/000520193.
Abdel-Rahman, O., & Koski, S. L. (2021). Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study. Neuroendocrinology, . https://doi.org/10.1159/000520193
Abdel-Rahman, Omar, and Koski, Sheryl L. "Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study." Neuroendocrinology vol. (2021). doi: https://doi.org/10.1159/000520193
Abdel-Rahman O, Koski SL. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study. Neuroendocrinology. 2021 Oct 14; doi: 10.1159/000520193. Epub 2021 Oct 14. PMID: 34649258.
Copy Download .nbib Format: NLM
Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy.

European journal of radiology

Wang Y, Chen J, Song C, Shi S, Li Z, Feng ST, Luo Y.
PMID: 34979297
Eur J Radiol. 2021 Dec 26;147:110119. doi: 10.1016/j.ejrad.2021.110119. Epub 2021 Dec 26.

OBJECTIVES: To identify early and more accurate imaging response criteria for computed tomography evaluation to define 'responders' in advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) patients treated with cisplatin/etoposide combined chemotherapy.MATERIALS AND METHODS: Thirty-seven patients with GEP-NEC treated with first-line cisplatin/etoposide...

Cite
Wang Y, Chen J, Song C, et al. Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. Eur J Radiol. 2021;147:110119doi: 10.1016/j.ejrad.2021.110119.
Wang, Y., Chen, J., Song, C., Shi, S., Li, Z., Feng, S. T., & Luo, Y. (2021). Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. European journal of radiology, 147110119. https://doi.org/10.1016/j.ejrad.2021.110119
Wang, Yangdi, et al. "Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy." European journal of radiology vol. 147 (2021): 110119. doi: https://doi.org/10.1016/j.ejrad.2021.110119
Wang Y, Chen J, Song C, Shi S, Li Z, Feng ST, Luo Y. Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. Eur J Radiol. 2021 Dec 26;147:110119. doi: 10.1016/j.ejrad.2021.110119. Epub 2021 Dec 26. PMID: 34979297.
Copy Download .nbib Format: NLM
Showing 1801 to 1811 of 1811 entries